Allergan Plc's Vraylar won US regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said.
Pediatric antipsychotic use is associated with an increase in body fat and decreases in insulin sensitivity, potentially raising the risk of premature cardiometabolic morbidity and mortality, researchers say.
People who have disrupted sleep cycles or less variation in their activity levels around the clock may be more likely to have depression, bipolar disorders and other mental health issues, a UK study suggests.
Stay in the know. Psychiatry and Behavioral Health Learning Network Newsletter